Clinical Trial Update: HAIC Combined With Durvalumab, Tremelimumab and Bevacizumab as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial assessing hepatic arterial infusion chemotherapy combined with durvalumab, tremelimumab, and bevacizumab as conversion therapy for potentially res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Durvalumab (durvalumab)
• HAIC (hepatic arterial infusion chemotherapy) (hepatic arterial infusion chemotherapy)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Unrescetable Hepatocellular Carcinoma | Phase 2 | Status: UNKNOWN